Breakfast

Perspectives on psoriasis: Exploring what matters most to you

Objectives:

1. Discuss the current state of psoriasis management by examining real world effectiveness of available treatments
2. Provide an update on efficacy and safety data of bimekizumab in patients with moderate-to-severe plaque psoriasis
3. Explore the impact that psoriasis and effective treatment has on the lives of patients with the disease

The Dynamic Skin Barrier and Why Formulation Matters

OBJECTIVES:

• Evaluate the skin barrier as a dynamic sophisticated structure.
• Analyze the research on products, ingredients and technologies that are gentle, effective and support the dynamic skin barrier.
• Describe criteria to consider when making product, ingredient, regimen recommendations to patients.

Make It PsO: The Next Generation of Topical Treatments

Objectives of the session:

1. Discuss unmet needs for topical treatments in the management of the chronic disease plaque psoriasis (PsO) from patients’ and physicians’ perspectives.
2. Review the benefits and challenges of current plaque PsO topical treatment approaches.
3. Examine next generation topical formulation considerations for the practical management of chronic plaque PsO.

Summary description of the session:

Join us for the second episode of PsO Let’s Talk with our expert guest host, Dr. Perla Lansang. For the past 60 years, topical therapies remain the foundation of chronic plaque PsO treatment, yet many unmet needs still exist. A novel non-steroidal topical treatment option has not been approved in Canada for over 20 years. Plaque PsO is a heterogenous and chronic disease, with almost 90% of patients experiencing PsO in more than one location with a median disease duration of 50 years; however, no one topical therapy safely addresses all affected areas and there are growing concerns, real and perceived, from patients as steroid-phobia continues to gain presence in many social media outlets. Dermatologists often need to prescribe PsO patients a complex regimen consisting of at least 2-3 different topicals of varying potencies, of which many may have treatment limitations due to adverse events compromising their acceptance by patients for chronic use. Additionally, despite the many currently available topical treatments, patients with plaque PsO still experience the highly disruptive symptom of itch that negatively affects their quality of life.

This open session will discuss current and new developments in topical treatment for chronic plaque PsO by examining efficacy, safety/tolerability, and vehicle formulation considerations towards the clinical goal for a simplified regimen. The expert speaker panel from the final frontier, Dr. Kim ‘Papp-card’ and Dr. ‘Bones’ Turchin, will ‘Make It PsO’ the audience gains a better understanding of the ongoing challenges in the management of this chronic auto-immune inflammatory skin condition, and how this next generation of topical non-steroidal therapy may address these unmet needs.

Let's Play Jeopardy - GPP edition

Objectives:

1. Recognize GPP as a distinct disease from plaque psoriasis, with distinct clinical features (Scholar, Health Advocate)
2. Appreciate the severity of GPP flares and their impact on quality of life (Health Advocate, Communicator)
3. Review current treatment approaches for GPP (Medical Expert, Professional)

An interactive learning program where dermatology contestants from across Canada will have the opportunity to test their GPP knowledge. Jeopardy will be hosted by Dr. Gurbir Dhadwal and dermatologists players from the East, West and Ontario will be competing for the title of "Champion - Jeopardy GPP Edition". The audience will be invited to play as well. Join us at this interactive session with the goal of having some fun while learning more about different perspectives and insights around GPP.

Lunch

Heads Up! A topline review of phase 3 clinical data in scalp psoriasis

Objectives:

After attending this program, attendees will be able to:

1. Recognize current unmet needs and challenges in the management of scalp psoriasis
2. Apply phase 3 trial data with tildrakizumab for the treatment of scalp psoriasis to clinical practice
3. Identify patients with scalp psoriasis for whom tildrakizumab is appropriate

Session description:
Data from Phase 3 clinical trials prospectively evaluating currently available biologics in the treatment of scalp psoriasis are limited. In this session, Phase 3 trial data assessing the efficacy and safety of tildrakizumab in the treatment of moderate-to-severe psoriasis of the scalp will be presented. To demonstrate how the trial data can translate into the real-world, a patient case will be shared. The session will conclude with an opportunity for the audience to pose questions.

A multicenter evaluation of a ceramide-containing hydrating cream-to-foam cleanser and facial moisturizing lotion for improving acne treatment tolerability and adherence

OBJECTIVE:
Evaluate the impact of a ceramide-containing hydrating cream-to-foam cleanser and PM facial moisturizing lotion on acne treatment tolerability and adherence.

Description:
Present and discuss the multicenter, open-label, cohort study of a topical retinoid and daily use of an adjunct cleanser and moisturizer to prevent adverse events and improve compliance with prescription acne treatments.

Unmasking Acne: A closer look at the unmet needs. A clearer view of the road ahead.

After attending this program, attendees will be able to:

1. Recognize current unmet needs in acne management
2. Explain the limitations of managing acne with currently available treatment options
3. Describe the role of androgens in acne pathophysiology, and select appropriate therapies targeting the androgen pathway

Session description:
Despite the acne treatment landscape continually evolving, there still remain significant unmet needs for patients suffering with moderate-to-severe acne. In this session, Dr. Jaggi Rao will discuss these patient needs, along with gaps and challenges of acne management in Canada, while Dr. Leon Kircik will provide insight into the experience of treating acne in the United States, including the use of the newly available topical agent – clascoterone. The presentations will be tied together through a discussion amongst the panelists led by Dr. Jerry Tan, and the session will conclude with an opportunity for the audience to pose questions to the panel.

JAK Inhibition: What It All Really Means

Arcutis Canada National Dermatology Advisory

Racial/Ethnic Variation AD Algorithm

Advisory Board

Pfizer Medical Advisory Board

Vichy Hyperpigmentation Advisory Board